Xencor Net Debt Over Time
| XNCR Stock | USD 25.01 0.91 3.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Xencor Performance and Xencor Correlation. Xencor |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xencor. If investors know Xencor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xencor listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.18) | Revenue Per Share 1.375 | Quarterly Revenue Growth (0.82) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Xencor Inc is measured differently than its book value, which is the value of Xencor that is recorded on the company's balance sheet. Investors also form their own opinion of Xencor's value that differs from its market value or its book value, called intrinsic value, which is Xencor's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xencor's market value can be influenced by many factors that don't directly affect Xencor's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xencor's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xencor is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xencor's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Debt Analysis
Compare Xencor Inc and related stocks such as Edgewise Therapeutics, Keros Therapeutics, and Monte Rosa Therapeutics Net Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EWTX | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 55.3 M | (280.8 M) | (347.5 M) | (80.7 M) | (84.7 M) |
| KROS | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (5.7 M) | (265 M) | (228.9 M) | (265.8 M) | (316.7 M) | (300.9 M) |
| GLUE | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | 26.1 M | (346.1 M) | (7.9 M) | (82.1 M) | (86.2 M) |
| MLYS | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | (10.6 M) | (87.7 M) | (49.3 M) | (51.8 M) |
| ERAS | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (25.9 M) | (62.4 M) | (341.7 M) | (229.1 M) | (37.2 M) | (39.1 M) |
| KURA | (7.5 K) | 115.8 K | 165.2 K | 213.4 K | 1.4 M | (15.4 M) | (2.4 M) | (4.3 M) | (8.6 M) | (18.6 M) | (310.5 M) | (83.8 M) | (37.8 M) | (20.1 M) | (21.1 M) |
| PTGX | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (4.1 M) | (21.1 M) | (106 M) | (82.2 M) | (16 M) | (111.4 M) | (117.8 M) | (122.1 M) | (185.6 M) | (176.3 M) |
| MRUS | (6.3 M) | (6.3 M) | (6.3 M) | (13.3 M) | (1.2 M) | (35.2 M) | (59.3 M) | (179.6 M) | (164.4 M) | (192.4 M) | (159.1 M) | (237.7 M) | (134.3 M) | (192.9 M) | (183.2 M) |
| REPL | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (17.6 M) | (19.1 M) | (17.7 M) | (149.2 M) | (73.1 M) | (85.8 M) | 1.4 M | 1.5 M |
| IDYA | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (20.5 M) | (27.3 M) | (65.3 M) | (86.9 M) | (65.2 M) | (154.1 M) | (146.4 M) |
| ANAB | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (17.3 M) | (46.8 M) | (37.4 M) | (66.7 M) | (105.3 M) | (168.8 M) | (250.1 M) | (474.8 M) | (51.9 M) | (18.2 M) | (19.1 M) |
| MGTX | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (7 M) | (68 M) | (204.1 M) | (187.3 M) | (114 M) | (23.3 M) | (40.3 M) | (42.3 M) |
| NUVL | (843 K) | (843 K) | (843 K) | (843 K) | (843 K) | (843 K) | (843 K) | (843 K) | (843 K) | (843 K) | (8.1 M) | (68.5 M) | (241.8 M) | (335.4 M) | (318.6 M) |
| ACLX | (34.6 M) | (34.6 M) | (34.6 M) | (34.6 M) | (34.6 M) | (34.6 M) | (34.6 M) | (34.6 M) | (34.6 M) | (34.6 M) | (46.6 M) | (104.5 M) | 24 M | (297 M) | (282.1 M) |
| PCVX | (65.6 M) | (65.6 M) | (65.6 M) | (65.6 M) | (65.6 M) | (65.6 M) | (65.6 M) | (65.6 M) | (65.6 M) | (58.8 M) | (386.2 M) | (52.2 M) | (816.7 M) | (368.2 M) | (386.6 M) |
| VRDN | 22.5 M | 22.5 M | 22.5 M | 487.7 K | (5 M) | (9.7 M) | (2.3 M) | (37.5 M) | (22.3 M) | (16.5 M) | (45.4 M) | (41.8 M) | (150.3 M) | (81.8 M) | (77.7 M) |
| LRMR | (50.5 M) | (50.5 M) | (50.5 M) | (50.5 M) | (50.5 M) | (29.2 M) | (28.8 M) | (20.8 M) | (28.7 M) | (912 K) | (61.6 M) | (64.1 M) | (21.4 M) | (21.2 M) | (22.3 M) |
| SNDX | 20.8 M | 20.8 M | 20.8 M | (10.1 M) | 3.9 M | (23.2 M) | (23.8 M) | (35.2 M) | (33.8 M) | (23.7 M) | (94.7 M) | (201 M) | (73.2 M) | (293.8 M) | (279.1 M) |
| STRO | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (7.4 M) | (110.6 M) | 4.9 M | (181.6 M) | 27 M | 20.3 M | (35.6 M) | (37.4 M) |
Xencor Inc and related stocks such as Edgewise Therapeutics, Keros Therapeutics, and Monte Rosa Therapeutics Net Debt description
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.My Equities
My Current Equities and Potential Positions
| Xencor Inc | XNCR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 25.01
Additional Tools for Xencor Stock Analysis
When running Xencor's price analysis, check to measure Xencor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xencor is operating at the current time. Most of Xencor's value examination focuses on studying past and present price action to predict the probability of Xencor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xencor's price. Additionally, you may evaluate how the addition of Xencor to your portfolios can decrease your overall portfolio volatility.